AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
Wayne State University · The Ohio State University · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
665
total citations
- FWCI
- 43.70
- Percentile
- 100%
- References
- 39
Citations per year
Authors
21Topics & keywords
Topics
Keywords
- Subthalamic nucleus
- Medicine
- Parkinsonism
- Parkinson's disease
- Clinical endpoint
- Randomized controlled trial
- Rating scale
- Levodopa
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- UDU.S. Department of Defense
- MJMichael J. Fox Foundation for Parkinson's Research
- HDHuntington's Disease Society of America
- BIBoehringer Ingelheim
- DFDana Foundation
- MMerck
- NNovartis
- TPTeva Pharmaceutical Industries
- APAlnylam Pharmaceuticals
- OSOhio State University
- SSchering-Plough
- BIBoehringer Ingelheim
- IPInternational Parkinson and Movement Disorder Society
- THThomas Hartman Foundation for Parkinson’s Research
- UUCB
- RURockefeller University
- PSParkinson Study Group
- APACADIA Pharmaceuticals
- HLH. Lundbeck A/S
- IIpsen
- NINational Institutes of Health
- WCWeill Cornell Medical College
- AAllergan
- NINational Institute of Neurological Disorders and Stroke